CYSTATIN S AS A MARKER OF CYCLOSPORINE A RENAL TOXICITY IN CHILDREN WITH NEPHROTIC SYNDROME
Abstract
The use of cystatin С as a probable marker of renal toxicity of cyclosporine A in children with nephritic syndrome, treated with this medication for a long time, is the subject of an interest. The present study included 29 children treated with cyclosporine A, divided into 3 groups depending on the duration of treatment (< 1 year, 1–2 years and > 2 years). The increase of cystatin С level in these groups compared with cystatin С level in control group (10 children without diseases of kidney) was marked. The highest level of cystatin С was detected in children treated with therapeutic doses of cyclosporine A (3–5 mg/kg daily) over 1 year. Authors showed positive correlation between cystatin С level in serum and medication’s dose.
Key words: children, nephritic syndrome, cystatin С, cyclosporine A.
(Voprosy sovremennoi pediatrii — Current Pediatrics. 2010;9(1):131-135)
About the Authors
O.V. KomarovaRussian Federation
M.V. Rozhkova
Russian Federation
A.N. Tsygin
Russian Federation
A.G. Kucherenko
Russian Federation
I.E. Smirnov
Russian Federation
L.V. Leonova
Russian Federation
References
1. Цыгин А.Н., Комарова О.В., Сергеева Т.В. и др. Нефротический синдром. Клинические рекомендации по педиатрии. Под ред. А.А. Баранова М.: ГЕОТАР–Медиа. 2009. C. 239–261.
2. Ponticelli C., Edefonti A., Ghio L. et al. Cyclosporine versus cyclophosphamide for patients with steroid dependent and frequently relapsing nephritic syndrome: a multicenter randomized controlled trial. Nephrol. Dial. Transplant. 1993; 8: 1326–1332.
3. Takeda A., Takimoto H., Mizusawa Y. еt al. Prediction of subsequent relapse in children with steroid-sensitive nephrotic syndrome. Pediatr. Nephrol. 2001; 16: 888–893.
4. Niaudet P. Long term outcome of children with steroid-sensitive idiopathic nephrotic syndrome. Clin. J. Am. Soc. Nephrol. 2009; 4: 1547–1548.
5. Cattran D.C., Alexopoulos E., Heering P. et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: Workshop recommendations. Kid. Int. 2007; 72: 1429–1447.
6. Комарова О.В., Цыгин А.Н., Леонова Л.В. и др. Терапия циклоспорином А детей с фокально-сегментарным гломерулосклерозом. Вопросы современной педиатрии. 2009; 8 (5): 93–97.
7. Meyrier A., Noel L.H., Auriche P. et al. Long term renal tolerance of cyclosporine A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Societe de Nephrologie. Kidney Int. 1994; 45 (5): 1446–1456.
8. El–Husseini A., El–Basuony F., Mahmoud I. et al. Long term effects of cyclosporine in children with idiopathic nephrotic syndrome: a single center experience. Nephrol. Dial. Transplant. 2005; 20 (11): 2433–2438.
9. Schiff J., Cole E., Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin. J. Am. Soc. Nephorl. 2007; 2: 374–384.
10. Seikaly M.G., Prashner H., Nolde–Hurlbert B., Browne R. Long term clinical and pathological effects of cyclosporine in children with nephrosis. Pediatr. Nephrol. 2000; 14: 214–217.
11. Kengne S.W., Massella L., Diomedi F.C. et al. Risk factors for cyclosporin A nephrotoxicity in children with steroid dependent nephrotic syndrome.
12. Clin. J. Am. Soc. Nephrol. 2009; 4 (9): 1409–1416.
13. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Am. J Kidney Dis. 2005; 1: 1–226.
14. Cockcroft D., Gault V. Prediction of creatinine clearance form serum creatinine. Nephron. 1976; 16: 31–41.
15. Pierrat A., Gravier E., Saundrs C. et al. Predicting GRF in children and adults: a comparison of the Cockcroft–Gault, Schwartz and Modification of diet in renal disease formulas. Kidney Int. 2003; 63: 1425–1436.
16. Schwartz G., Haycock G., Edelmann C. et al. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics. 1976; 58: 259–263.
17. Schwartz G.J., Furth S., Cole S.R. et al. Glomerular filtration rate via plazma iohexol disappearance: pilot study for chronic kidney disease in children. Kidney Int. 2006; 69: 2070–2077.
18. Mattman A., Eintracht S., Moch T. et al. Estimating pediatric glomerular filtration rates in the era of chronic kidney disease staging. J. Am. Soc. Nephrol. 2006; 17 (2): 487–496.
19. Kyhse-Anderson J., Schmidt C., Nordin G. et al. Serum cystatin C, determined by a rapid, automated particle enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin. Chem. 1994; 40: 1921–1926.
20. Wu I., Parikh C.R. Screening for kidney diseases: older measures versus novel biomarkers. Clin. J. Am. Soc. Nephrol. 2008; 3: 1895–1901.
21. Bökenkamp A., Domanetzki M., Zinck R. et al. Reference values for cystatin C serum concentrations in children. Pediatr. Nephrol. 1998; 12: 125–129.
22. Coll E., Botey A., Alvarez L. et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am. J. Kidney Dis. 2000; 36: 29–34.
23. Резниченко Н.Е., Панфилова Е.Ю., Данкавцева Е.Н. и др. Возможности использования цистатина в кардиологии. Медицинский алфавит. Больница. 2009; 3: 23–26.
24. Premaratne E., Maclsaac R., Finch S. et al. Serial measurements of cystatin C are more accurate than creatinine based methods in detecting declining renal function in type 1 diabetes. Diabetes Care. 2008; 31 (5): 971–973.
25. Hoek F., Kemperman F., Krediet R. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol. Dial. Transplant. 2003; 18: 2024–2031.
26. Stevens L., Coresh J., Schmid C. et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am. J. Kidney Dis. 2008; 51 (3): 395–406.
27. Zahran A., Qureshi M., Shoker A. Comparison between creatinine and cystatin C-based GFR equations in renal transplantation. Nephrol. Dial. Transplant. 2007; 22: 2659–2668.
28. Tanaka A., Aiba T., Otsuka T. et al. Population pharmacokinetic analysis of vancomycin using serum cystatin–C as a marker of renal function. Antimicrob. Agents Chemother. 2009. URL: http://aac.asm.org/cgi/content/abstract/54/2/778
29. Filler G., Priem F., Vollmer I. et al. Diagnostic sensitivity of serum cystatin for impaired glomerular filtration rate. Ped. Nephrol. 1999; 13: 501–505.
30. Короленко Т.А., Черканова М.С., Филатова Т.Г. и др. Возрастные изменения содержания цистатина С и С–реактивного белка у здоровых лиц. Terra medica nova. 2007; 1: 13.
Review
For citations:
Komarova O., Rozhkova M., Tsygin A., Kucherenko A., Smirnov I., Leonova L. CYSTATIN S AS A MARKER OF CYCLOSPORINE A RENAL TOXICITY IN CHILDREN WITH NEPHROTIC SYNDROME. Current Pediatrics. 2010;9(1):131-135.
Email this article 
